554 related articles for article (PubMed ID: 19060584)
1. Biochemical and functional outcomes following brachytherapy with or without supplemental therapies in men < or = 50 years of age with clinically organ-confined prostate cancer.
Merrick GS; Wallner KE; Galbreath RW; Butler WM; Brammer SG; Allen ZA; Lief JH; Adamovich E
Am J Clin Oncol; 2008 Dec; 31(6):539-44. PubMed ID: 19060584
[TBL] [Abstract][Full Text] [Related]
2. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
Urology; 2004 Oct; 64(4):754-9. PubMed ID: 15491715
[TBL] [Abstract][Full Text] [Related]
3. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
[TBL] [Abstract][Full Text] [Related]
4. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198
[TBL] [Abstract][Full Text] [Related]
5. Brachytherapy in men aged < or = 54 years with clinically localized prostate cancer.
Merrick GS; Wallner KE; Butler WM; Galbreath RW; Allen ZA; Adamovich E; True L
BJU Int; 2006 Aug; 98(2):324-8. PubMed ID: 16879672
[TBL] [Abstract][Full Text] [Related]
6. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
[TBL] [Abstract][Full Text] [Related]
7. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men agedGómez-Iturriaga Piña A; Crook J; Borg J; Lockwood G; Fleshner N
Urology; 2010 Jun; 75(6):1412-6. PubMed ID: 20035986
[TBL] [Abstract][Full Text] [Related]
8. Prostate brachytherapy in men > or =75 years of age.
Merrick GS; Wallner KE; Galbreath RW; Butler WM; Brammer SG; Allen ZA; Adamovich E
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):415-20. PubMed ID: 18374514
[TBL] [Abstract][Full Text] [Related]
9. Effect of cigarette smoking on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1056-62. PubMed ID: 15001245
[TBL] [Abstract][Full Text] [Related]
10. Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy.
Taira AV; Merrick GS; Galbreath RW; Wallner KE; Butler WM
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):349-54. PubMed ID: 19467793
[TBL] [Abstract][Full Text] [Related]
11. Perineural invasion is not predictive of biochemical outcome following prostate brachytherapy.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Cancer J; 2001; 7(5):404-12. PubMed ID: 11693899
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E; Lief J
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):34-40. PubMed ID: 17289288
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen (PSA) velocity and benign prostate hypertrophy predict for PSA spikes following prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Lief JH; Hinerman-Mulroy A; Galbreath RW
Brachytherapy; 2003; 2(3):181-8. PubMed ID: 15062141
[TBL] [Abstract][Full Text] [Related]
14. Permanent prostate brachytherapy in prostate glands <20 cm(3).
Mayadev J; Merrick GS; Reed JR; Butler WM; Galbreath RW; Allen ZA; Wallner KE
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1450-5. PubMed ID: 20338476
[TBL] [Abstract][Full Text] [Related]
15. High-risk prostate cancer with Gleason score 8-10 and PSA level ≤15 ng/mL treated with permanent interstitial brachytherapy.
Fang LC; Merrick GS; Butler WM; Galbreath RW; Murray BC; Reed JL; Adamovich E; Wallner KE
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):992-6. PubMed ID: 20932674
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features.
Dattoli M; Wallner K; True L; Cash J; Sorace R
Cancer; 2007 Aug; 110(3):551-5. PubMed ID: 17577217
[TBL] [Abstract][Full Text] [Related]
17. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy.
Aaronson DS; Yamasaki I; Gottschalk A; Speight J; Hsu IC; Pickett B; Roach M; Shinohara K
BJU Int; 2009 Sep; 104(5):600-4. PubMed ID: 19245439
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes in younger men following permanent prostate brachytherapy.
Shapiro EY; Rais-Bahrami S; Morgenstern C; Napolitano B; Richstone L; Potters L
J Urol; 2009 Apr; 181(4):1665-71; discussion 1671. PubMed ID: 19233394
[TBL] [Abstract][Full Text] [Related]
19. Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):669-77. PubMed ID: 16682149
[TBL] [Abstract][Full Text] [Related]
20. 20 Gy versus 44 Gy of supplemental external beam radiotherapy with palladium-103 for patients with greater risk disease: results of a prospective randomized trial.
Merrick GS; Wallner KE; Butler WM; Galbreath RW; Taira AV; Orio P; Adamovich E
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e449-55. PubMed ID: 22196131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]